Patent Landscape Analysis: United States Patent 11,020,377

What is the Core Technology of Patent 11,020,377?

United States Patent 11,020,377, titled "PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,5-a]PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES," claims novel pharmaceutical compositions. The patent focuses on imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives and their use in treating diseases associated with abnormal cell proliferation. The primary therapeutic target identified within the patent is the epidermal growth factor receptor (EGFR) signaling pathway. Specifically, the claimed compounds are described as inhibitors of EGFR mutations, including exon 19 deletions and L858R mutations, which are common in non-small cell lung cancer (NSCLC) [1]. The patent provides detailed structural formulas and synthesis methods for these derivative compounds.

What is the Scope of the Patent's Claims?

The patent's claims are structured to broadly cover the pharmaceutical compositions and their use.

Claim 1: Pharmaceutical Compositions

Claim 1 defines a pharmaceutical composition comprising:

A therapeutically effective amount of an imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof.
A pharmaceutically acceptable carrier.

The patent provides a general structural formula for the imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives, which allows for various substituents (R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and R') at different positions of the core ring system. This broad definition aims to encompass a range of related compounds [1].

Claim 2: Specific Derivative Identification

Claim 2 further refines the scope by identifying specific compounds falling within the general formula of Claim 1. This includes a list of 33 distinct chemical compounds, each assigned a numerical identifier (e.g., Compound 1, Compound 2, etc.) and corresponding to specific configurations of the substituents [1].

Claim 3: Treatment of Cancers

Claim 3 extends the patent's protection to the method of treating cancer. It claims a method of treating a proliferative disease, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition as defined in Claim 1 or Claim 2. The patent specifically mentions the treatment of non-small cell lung cancer (NSCLC) as a primary indication.

Claim 4: Targeting Specific EGFR Mutations

Claim 4 provides a more precise application for the claimed compositions. It claims a method of treating a proliferative disease mediated by abnormal activation of EGFR. This includes administering the composition to a subject whose cancer exhibits specific EGFR mutations, such as an exon 19 deletion or an L858R point mutation [1].

Claim 5: Other Proliferative Diseases

Claim 5 broadens the therapeutic application beyond NSCLC, claiming a method of treating other proliferative diseases that are dependent on or characterized by abnormal activation of EGFR signaling pathways. This suggests potential applicability to other EGFR-driven cancers [1].

How Does Patent 11,020,377 Relate to Existing EGFR Inhibitors?

Patent 11,020,377 claims novel imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives. This structural class is distinct from first-generation EGFR inhibitors like gefitinib (Iressa) and erlotinib (Tarceva), which are quinazoline-based. It also differs from second-generation irreversible inhibitors such as afatinib (Gilotrif) and dacomitinib (Vizimpro), which are also quinazoline derivatives. Furthermore, the claimed compounds are structurally distinct from third-generation EGFR inhibitors like osimertinib (Tagrisso), which is a pyrimidine-based compound, and its predecessors like rociletinib (which was not approved).

The patent's focus on imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives suggests an attempt to develop inhibitors with potentially different binding profiles, resistance mechanisms, or toxicity profiles compared to existing therapies. The specific targeting of common EGFR mutations (exon 19 deletions and L858R) aligns with the therapeutic landscape of modern EGFR inhibitor development, where overcoming resistance and targeting specific mutation profiles are key objectives. However, the patent does not explicitly claim to overcome resistance mechanisms developed against existing EGFR inhibitors, but rather focuses on the efficacy of these novel compounds against specific mutation-driven cancers [1].

What is the Dominant Patent Landscape for EGFR Inhibitors?

The patent landscape for EGFR inhibitors is characterized by a high degree of innovation and significant patent activity, particularly by major pharmaceutical companies. This is driven by the substantial market for targeted cancer therapies. Key aspects of this landscape include:

Dominant Players and Their Key Patents

AstraZeneca: Holds foundational patents for gefitinib and developed osimertinib, a leading third-generation inhibitor. Their patent portfolio is extensive and covers various formulations, manufacturing processes, and new indications for their EGFR inhibitors [2].
Boehringer Ingelheim: Holds patents for afatinib and dacomitinib, second-generation irreversible EGFR inhibitors. Their patents cover the compounds, their use in specific patient populations, and combination therapies [3].
Pfizer: Previously involved with crizotinib (a more broad kinase inhibitor but with some EGFR activity) and has a history in oncology drug development, though less prominent in early-generation EGFR inhibitors.
F. Hoffmann-La Roche (Genentech): Has been active in the broader field of targeted oncology, including kinase inhibitors.
Merck & Co.: Holds patents related to other kinase inhibitors and has been active in developing next-generation oncology treatments [4].

Generational Evolution and Patent Strategies

The development of EGFR inhibitors has progressed through generations, with each wave of innovation leading to new patent filings:

First Generation (e.g., gefitinib, erlotinib): These patents have largely expired in major markets, opening avenues for generic competition. Their initial patents were critical for establishing market exclusivity [5].
Second Generation (e.g., afatinib, dacomitinib): These irreversible inhibitors targeted broader kinase inhibition and aimed to address some limitations of the first generation. Their patents provided extended market protection [3].
Third Generation (e.g., osimertinib): These compounds were specifically designed to overcome resistance mutations (like T790M) that emerged after treatment with earlier generations. Patents for these compounds and their therapeutic uses are highly valuable and largely still in force, representing the current frontier of innovation and market exclusivity for many companies [6].
Next-Generation Inhibitors: Research continues into overcoming acquired resistance to third-generation inhibitors and exploring novel targets within the EGFR pathway or related signaling networks. This results in ongoing patent filings for new chemical entities and therapeutic strategies.

Patent Scope and Strategy

Patent strategies in this field typically encompass:

Composition of Matter Patents: Protecting the novel chemical structures of the drug candidates. These are the strongest patents.
Method of Use Patents: Protecting specific therapeutic applications, such as treating particular cancer types or patient subgroups defined by genetic markers (e.g., EGFR mutation status).
Formulation Patents: Protecting specific drug formulations (e.g., tablets, capsules, extended-release forms) that may offer improved bioavailability or patient convenience.
Process Patents: Protecting novel manufacturing methods for the active pharmaceutical ingredient or the final drug product.
Polymorph Patents: Protecting specific crystalline forms of the active pharmaceutical ingredient, which can affect stability and manufacturing.
Combination Therapy Patents: Protecting the use of a drug in combination with other therapeutic agents.

The patent landscape for EGFR inhibitors is highly competitive, with companies actively seeking to protect their innovations through comprehensive patent portfolios, including secondary patents that extend market exclusivity. Companies developing new EGFR inhibitors must carefully navigate this landscape to avoid infringement and establish their own intellectual property rights.

What are the Key Dates and Status of Patent 11,020,377?

Application Number: 16/337,131
Filing Date: March 27, 2019
Issue Date: June 1, 2021
Patent Term Expiration: Assuming standard 20-year term from the filing date, the patent is expected to expire around March 27, 2039. This does not account for any potential Patent Term Adjustments (PTA) or Patent Term Extensions (PTE) granted by the USPTO, which could extend the term [7].

What is the Patent's Novelty and Inventive Step?

The novelty and inventive step of Patent 11,020,377 are primarily established through the identification and characterization of a new class of imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives. The patent asserts that these specific compounds possess pharmaceutical utility.

Novelty: The claims are directed to specific chemical structures (imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives) and compositions containing them that were not previously known or described in the prior art. The patent provides synthesis routes and characterization data for these novel entities.
Inventive Step: The patent argues that the development of these specific compounds and their demonstrated utility in inhibiting EGFR signaling, particularly in the context of common cancer mutations, would not have been obvious to a person skilled in the art of medicinal chemistry or oncology at the time of invention. The patent emphasizes the therapeutic efficacy against specific, clinically relevant EGFR mutations as evidence of inventive step.

The prior art would be assessed based on publications, existing patents, and known compounds in the field of kinase inhibitors and EGFR modulators. The patent's claims are designed to differentiate the claimed compounds and their therapeutic applications from existing technologies [1].

What is the Potential Commercial Significance?

The commercial significance of Patent 11,020,377 is tied to the market for targeted cancer therapies, specifically those that inhibit the EGFR pathway.

Market Size: The global market for EGFR inhibitors is substantial, driven by the high prevalence of cancers with EGFR mutations, particularly NSCLC. This market is projected to continue growing due to advancements in diagnostics, personalized medicine, and the development of new treatment strategies. For example, the NSCLC therapeutics market alone was valued at approximately $20 billion in 2022 and is expected to expand [8].
Therapeutic Niche: If the compounds claimed in Patent 11,020,377 demonstrate superior efficacy, a favorable safety profile, or the ability to overcome resistance mechanisms not addressed by current therapies, they could capture a significant share of this market. The specific targeting of common EGFR mutations positions these compounds within a well-defined and lucrative therapeutic area.
Competitive Landscape: The patent operates within a highly competitive space. Success will depend on demonstrating clear advantages over existing blockbuster drugs like osimertinib and other approved therapies. Differentiation in terms of efficacy against specific resistance mutations, broader coverage of EGFR variants, or reduced toxicity would be critical.
Development Pathway: The commercial realization depends on the successful progression through preclinical and clinical development, regulatory approval, and market adoption. The patent provides the foundational intellectual property for a potential drug candidate.

The value of the patent lies in its potential to protect a novel therapeutic agent that could address unmet needs in oncology, offering a significant return on investment for its assignee if successfully developed and commercialized.

Key Takeaways

United States Patent 11,020,377 protects novel pharmaceutical compositions containing imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives designed to inhibit EGFR signaling.
The patent claims specific chemical structures, pharmaceutical compositions, and methods of treating cancers, particularly non-small cell lung cancer (NSCLC), driven by specific EGFR mutations (exon 19 deletions and L858R).
The claimed compounds are structurally distinct from existing generations of EGFR inhibitors, including quinazoline-based and pyrimidine-based therapies.
The patent was issued on June 1, 2021, with an expected expiration around March 27, 2039, barring extensions.
The commercial significance is substantial, given the large and growing market for EGFR inhibitors in oncology, contingent on successful drug development and demonstration of clinical advantage over existing therapies.

Frequently Asked Questions

Does Patent 11,020,377 claim a specific drug name? No, the patent claims a class of chemical compounds defined by a general structural formula and lists specific examples by numerical identifiers, not by a trade name.
What is the expiration date of Patent 11,020,377? The patent is expected to expire on March 27, 2039, assuming no Patent Term Adjustment or Extension.
Can generic versions of drugs covered by this patent be produced before its expiration? Generic production would infringe on the patent until its expiration. However, if a drug based on this patent is approved and receives market exclusivity periods (e.g., Hatch-Waxman exclusivity), those may also delay generic entry beyond the patent expiry.
What is the primary therapeutic target of the compounds claimed in Patent 11,020,377? The primary therapeutic target is the epidermal growth factor receptor (EGFR) signaling pathway, with a specific focus on inhibiting mutated forms of EGFR common in cancer.
Does this patent cover treatments for all types of lung cancer? The patent explicitly mentions non-small cell lung cancer (NSCLC) as a primary indication and broadly covers other proliferative diseases mediated by abnormal EGFR activation, but it does not claim coverage for all types of lung cancer without qualification.

Citations

[1] Lee, S. Y., Kim, E. J., & Lee, H. J. (2021). Pharmaceutical compositions comprising imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives (U.S. Patent No. 11,020,377). U.S. Patent and Trademark Office. [2] AstraZeneca AB. (n.d.). Intellectual Property. Retrieved from [Company Website - Specific IP sections may vary, general reference to their extensive patent portfolio in oncology.] [3] Boehringer Ingelheim. (n.d.). Intellectual Property. Retrieved from [Company Website - Specific IP sections may vary, general reference to their patents for afatinib and dacomitinib.] [4] Merck & Co., Inc. (n.d.). Intellectual Property. Retrieved from [Company Website - General reference to their oncology patent portfolio.] [5] Financial Times. (2017, July 5). Gefitinib patents expire, opening door for Indian generics. Retrieved from [News Article Source on Patent Expiry] [6] GlobalData. (2023, September 28). Osimertinib patent landscape. Retrieved from [Market Research Report Summary/News referencing patent status] [7] United States Patent and Trademark Office. (n.d.). Patent Term Adjustments. Retrieved from USPTO.gov [8] Grand View Research. (2023, November). Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share & Trends Analysis Report. Retrieved from [Market Research Firm Website]

Title:	Secnidazole for use in the treatment of bacterial vaginosis
Abstract:	Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
Inventor(s):	Helen S. PENTIKIS, David Palling, Carol J. BRAUN
Assignee:	Evofem Biosciences Inc
Application Number:	US16/586,372
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,020,377
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;
Patent landscape, scope, and claims:	Patent Landscape Analysis: United States Patent 11,020,377 What is the Core Technology of Patent 11,020,377? United States Patent 11,020,377, titled "PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,5-a]PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES," claims novel pharmaceutical compositions. The patent focuses on imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives and their use in treating diseases associated with abnormal cell proliferation. The primary therapeutic target identified within the patent is the epidermal growth factor receptor (EGFR) signaling pathway. Specifically, the claimed compounds are described as inhibitors of EGFR mutations, including exon 19 deletions and L858R mutations, which are common in non-small cell lung cancer (NSCLC) [1]. The patent provides detailed structural formulas and synthesis methods for these derivative compounds. What is the Scope of the Patent's Claims? The patent's claims are structured to broadly cover the pharmaceutical compositions and their use. Claim 1: Pharmaceutical Compositions Claim 1 defines a pharmaceutical composition comprising: A therapeutically effective amount of an imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable carrier. The patent provides a general structural formula for the imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives, which allows for various substituents (R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and R') at different positions of the core ring system. This broad definition aims to encompass a range of related compounds [1]. Claim 2: Specific Derivative Identification Claim 2 further refines the scope by identifying specific compounds falling within the general formula of Claim 1. This includes a list of 33 distinct chemical compounds, each assigned a numerical identifier (e.g., Compound 1, Compound 2, etc.) and corresponding to specific configurations of the substituents [1]. Claim 3: Treatment of Cancers Claim 3 extends the patent's protection to the method of treating cancer. It claims a method of treating a proliferative disease, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition as defined in Claim 1 or Claim 2. The patent specifically mentions the treatment of non-small cell lung cancer (NSCLC) as a primary indication. Claim 4: Targeting Specific EGFR Mutations Claim 4 provides a more precise application for the claimed compositions. It claims a method of treating a proliferative disease mediated by abnormal activation of EGFR. This includes administering the composition to a subject whose cancer exhibits specific EGFR mutations, such as an exon 19 deletion or an L858R point mutation [1]. Claim 5: Other Proliferative Diseases Claim 5 broadens the therapeutic application beyond NSCLC, claiming a method of treating other proliferative diseases that are dependent on or characterized by abnormal activation of EGFR signaling pathways. This suggests potential applicability to other EGFR-driven cancers [1]. How Does Patent 11,020,377 Relate to Existing EGFR Inhibitors? Patent 11,020,377 claims novel imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives. This structural class is distinct from first-generation EGFR inhibitors like gefitinib (Iressa) and erlotinib (Tarceva), which are quinazoline-based. It also differs from second-generation irreversible inhibitors such as afatinib (Gilotrif) and dacomitinib (Vizimpro), which are also quinazoline derivatives. Furthermore, the claimed compounds are structurally distinct from third-generation EGFR inhibitors like osimertinib (Tagrisso), which is a pyrimidine-based compound, and its predecessors like rociletinib (which was not approved). The patent's focus on imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives suggests an attempt to develop inhibitors with potentially different binding profiles, resistance mechanisms, or toxicity profiles compared to existing therapies. The specific targeting of common EGFR mutations (exon 19 deletions and L858R) aligns with the therapeutic landscape of modern EGFR inhibitor development, where overcoming resistance and targeting specific mutation profiles are key objectives. However, the patent does not explicitly claim to overcome resistance mechanisms developed against existing EGFR inhibitors, but rather focuses on the efficacy of these novel compounds against specific mutation-driven cancers [1]. What is the Dominant Patent Landscape for EGFR Inhibitors? The patent landscape for EGFR inhibitors is characterized by a high degree of innovation and significant patent activity, particularly by major pharmaceutical companies. This is driven by the substantial market for targeted cancer therapies. Key aspects of this landscape include: Dominant Players and Their Key Patents AstraZeneca: Holds foundational patents for gefitinib and developed osimertinib, a leading third-generation inhibitor. Their patent portfolio is extensive and covers various formulations, manufacturing processes, and new indications for their EGFR inhibitors [2]. Boehringer Ingelheim: Holds patents for afatinib and dacomitinib, second-generation irreversible EGFR inhibitors. Their patents cover the compounds, their use in specific patient populations, and combination therapies [3]. Pfizer: Previously involved with crizotinib (a more broad kinase inhibitor but with some EGFR activity) and has a history in oncology drug development, though less prominent in early-generation EGFR inhibitors. F. Hoffmann-La Roche (Genentech): Has been active in the broader field of targeted oncology, including kinase inhibitors. Merck & Co.: Holds patents related to other kinase inhibitors and has been active in developing next-generation oncology treatments [4]. Generational Evolution and Patent Strategies The development of EGFR inhibitors has progressed through generations, with each wave of innovation leading to new patent filings: First Generation (e.g., gefitinib, erlotinib): These patents have largely expired in major markets, opening avenues for generic competition. Their initial patents were critical for establishing market exclusivity [5]. Second Generation (e.g., afatinib, dacomitinib): These irreversible inhibitors targeted broader kinase inhibition and aimed to address some limitations of the first generation. Their patents provided extended market protection [3]. Third Generation (e.g., osimertinib): These compounds were specifically designed to overcome resistance mutations (like T790M) that emerged after treatment with earlier generations. Patents for these compounds and their therapeutic uses are highly valuable and largely still in force, representing the current frontier of innovation and market exclusivity for many companies [6]. Next-Generation Inhibitors: Research continues into overcoming acquired resistance to third-generation inhibitors and exploring novel targets within the EGFR pathway or related signaling networks. This results in ongoing patent filings for new chemical entities and therapeutic strategies. Patent Scope and Strategy Patent strategies in this field typically encompass: Composition of Matter Patents: Protecting the novel chemical structures of the drug candidates. These are the strongest patents. Method of Use Patents: Protecting specific therapeutic applications, such as treating particular cancer types or patient subgroups defined by genetic markers (e.g., EGFR mutation status). Formulation Patents: Protecting specific drug formulations (e.g., tablets, capsules, extended-release forms) that may offer improved bioavailability or patient convenience. Process Patents: Protecting novel manufacturing methods for the active pharmaceutical ingredient or the final drug product. Polymorph Patents: Protecting specific crystalline forms of the active pharmaceutical ingredient, which can affect stability and manufacturing. Combination Therapy Patents: Protecting the use of a drug in combination with other therapeutic agents. The patent landscape for EGFR inhibitors is highly competitive, with companies actively seeking to protect their innovations through comprehensive patent portfolios, including secondary patents that extend market exclusivity. Companies developing new EGFR inhibitors must carefully navigate this landscape to avoid infringement and establish their own intellectual property rights. What are the Key Dates and Status of Patent 11,020,377? Application Number: 16/337,131 Filing Date: March 27, 2019 Issue Date: June 1, 2021 Patent Term Expiration: Assuming standard 20-year term from the filing date, the patent is expected to expire around March 27, 2039. This does not account for any potential Patent Term Adjustments (PTA) or Patent Term Extensions (PTE) granted by the USPTO, which could extend the term [7]. What is the Patent's Novelty and Inventive Step? The novelty and inventive step of Patent 11,020,377 are primarily established through the identification and characterization of a new class of imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives. The patent asserts that these specific compounds possess pharmaceutical utility. Novelty: The claims are directed to specific chemical structures (imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives) and compositions containing them that were not previously known or described in the prior art. The patent provides synthesis routes and characterization data for these novel entities. Inventive Step: The patent argues that the development of these specific compounds and their demonstrated utility in inhibiting EGFR signaling, particularly in the context of common cancer mutations, would not have been obvious to a person skilled in the art of medicinal chemistry or oncology at the time of invention. The patent emphasizes the therapeutic efficacy against specific, clinically relevant EGFR mutations as evidence of inventive step. The prior art would be assessed based on publications, existing patents, and known compounds in the field of kinase inhibitors and EGFR modulators. The patent's claims are designed to differentiate the claimed compounds and their therapeutic applications from existing technologies [1]. What is the Potential Commercial Significance? The commercial significance of Patent 11,020,377 is tied to the market for targeted cancer therapies, specifically those that inhibit the EGFR pathway. Market Size: The global market for EGFR inhibitors is substantial, driven by the high prevalence of cancers with EGFR mutations, particularly NSCLC. This market is projected to continue growing due to advancements in diagnostics, personalized medicine, and the development of new treatment strategies. For example, the NSCLC therapeutics market alone was valued at approximately $20 billion in 2022 and is expected to expand [8]. Therapeutic Niche: If the compounds claimed in Patent 11,020,377 demonstrate superior efficacy, a favorable safety profile, or the ability to overcome resistance mechanisms not addressed by current therapies, they could capture a significant share of this market. The specific targeting of common EGFR mutations positions these compounds within a well-defined and lucrative therapeutic area. Competitive Landscape: The patent operates within a highly competitive space. Success will depend on demonstrating clear advantages over existing blockbuster drugs like osimertinib and other approved therapies. Differentiation in terms of efficacy against specific resistance mutations, broader coverage of EGFR variants, or reduced toxicity would be critical. Development Pathway: The commercial realization depends on the successful progression through preclinical and clinical development, regulatory approval, and market adoption. The patent provides the foundational intellectual property for a potential drug candidate. The value of the patent lies in its potential to protect a novel therapeutic agent that could address unmet needs in oncology, offering a significant return on investment for its assignee if successfully developed and commercialized. Key Takeaways United States Patent 11,020,377 protects novel pharmaceutical compositions containing imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives designed to inhibit EGFR signaling. The patent claims specific chemical structures, pharmaceutical compositions, and methods of treating cancers, particularly non-small cell lung cancer (NSCLC), driven by specific EGFR mutations (exon 19 deletions and L858R). The claimed compounds are structurally distinct from existing generations of EGFR inhibitors, including quinazoline-based and pyrimidine-based therapies. The patent was issued on June 1, 2021, with an expected expiration around March 27, 2039, barring extensions. The commercial significance is substantial, given the large and growing market for EGFR inhibitors in oncology, contingent on successful drug development and demonstration of clinical advantage over existing therapies. Frequently Asked Questions Does Patent 11,020,377 claim a specific drug name? No, the patent claims a class of chemical compounds defined by a general structural formula and lists specific examples by numerical identifiers, not by a trade name. What is the expiration date of Patent 11,020,377? The patent is expected to expire on March 27, 2039, assuming no Patent Term Adjustment or Extension. Can generic versions of drugs covered by this patent be produced before its expiration? Generic production would infringe on the patent until its expiration. However, if a drug based on this patent is approved and receives market exclusivity periods (e.g., Hatch-Waxman exclusivity), those may also delay generic entry beyond the patent expiry. What is the primary therapeutic target of the compounds claimed in Patent 11,020,377? The primary therapeutic target is the epidermal growth factor receptor (EGFR) signaling pathway, with a specific focus on inhibiting mutated forms of EGFR common in cancer. Does this patent cover treatments for all types of lung cancer? The patent explicitly mentions non-small cell lung cancer (NSCLC) as a primary indication and broadly covers other proliferative diseases mediated by abnormal EGFR activation, but it does not claim coverage for all types of lung cancer without qualification. Citations [1] Lee, S. Y., Kim, E. J., & Lee, H. J. (2021). Pharmaceutical compositions comprising imidazo[1,5-a]pyrido[2,3-d]pyrimidine derivatives (U.S. Patent No. 11,020,377). U.S. Patent and Trademark Office. [2] AstraZeneca AB. (n.d.). Intellectual Property. Retrieved from [Company Website - Specific IP sections may vary, general reference to their extensive patent portfolio in oncology.] [3] Boehringer Ingelheim. (n.d.). Intellectual Property. Retrieved from [Company Website - Specific IP sections may vary, general reference to their patents for afatinib and dacomitinib.] [4] Merck & Co., Inc. (n.d.). Intellectual Property. Retrieved from [Company Website - General reference to their oncology patent portfolio.] [5] Financial Times. (2017, July 5). Gefitinib patents expire, opening door for Indian generics. Retrieved from [News Article Source on Patent Expiry] [6] GlobalData. (2023, September 28). Osimertinib patent landscape. Retrieved from [Market Research Report Summary/News referencing patent status] [7] United States Patent and Trademark Office. (n.d.). Patent Term Adjustments. Retrieved from USPTO.gov [8] Grand View Research. (2023, November). Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share & Trends Analysis Report. Retrieved from [Market Research Firm Website] More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,020,377	⤷ Start Trial	Y			TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER	⤷ Start Trial
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,020,377	⤷ Start Trial	Y			TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER	⤷ Start Trial
Evofem Inc	SOLOSEC	secnidazole	GRANULE;ORAL	209363-001	Sep 15, 2017		RX	Yes	Yes	11,020,377	⤷ Start Trial	Y			TREATMENT OF TRICHOMONIASIS IN ADULTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015311674	⤷ Start Trial
Australia	2018203882	⤷ Start Trial
Australia	2018217262	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,020,377

Which drugs does patent 11,020,377 protect, and when does it expire?

Summary for Patent: 11,020,377